Product
LB2102
1 clinical trial
2 indications
Indication
Extensive-Stage Small Cell Lung CancerClinical trial
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2028-01-01